GlassScriptPhysician profile
Laura J Cesario
NPI 1750892634
$9,123.58
in general payments reported to CMS, 2019-2025
38 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,102 · 2022: $1,534 · 2023: $1,413 · 2024: $1,870 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,449 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,448.75 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,435.77 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $961.31 | 2021-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $676.38 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $651.70 | 2021-2025 | Entyvio, Trintellix, Eohilia |
| Otsuka America Pharmaceutical, INC. | $471.76 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $444.66 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $340.25 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Janssen Biotech, INC. | $319.40 | 2021-2024 | Stelara, Tremfya |
| Alkermes, INC. | $289.14 | 2022-2024 | Aristada, Lybalvi, Aristada Initio |
| Intercept Pharmaceuticals, INC. | $250.47 | 2021-2022 | |
| Daiichi Sankyo INC. | $241.21 | 2021-2022 | |
| Gilead Sciences, INC. | $174.20 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $168.17 | 2021-2022 | |
| Medtronic, INC. | $139.06 | 2023-2025 | Interstim |
| Redhill Biopharma INC. | $130.85 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $130.69 | 2021-2022 | |
| Lundbeck LLC | $123.51 | 2022-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $111.96 | 2022-2024 | Ingrezza |
| Genzyme Corporation | $103.30 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $95.60 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.91 | 2024 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $90.72 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $82.52 | 2022-2024 | Invega Sustenna, Invega, Invega Trinza |
| Ardelyx, INC. | $75.27 | 2022-2025 | Ibsrela |
| Alfasigma USA, INC. | $72.37 | 2021 | |
| Corium, LLC | $71.32 | 2023-2024 | Azstarys |
| Noven Therapeutics, LLC | $65.23 | 2022-2023 | Xelstrym |
| Merck Sharp & Dohme LLC | $58.66 | 2021-2022 | |
| Lilly USA, LLC | $53.88 | 2024-2025 | Omvoh |
| Almatica Pharma LLC | $45.28 | 2023-2024 | Loreev Xr |
| Celgene Corporation | $41.65 | 2021-2022 | |
| Tris Pharma INC | $21.27 | 2024 | Dyanavel Xr |
| Axonics, INC. | $20.00 | 2021 | |
| Novo Nordisk INC | $19.56 | 2025 | Wegovy |
| Indivior INC. | $16.39 | 2024 | Perseris |
| Evoke Pharma, INC. | $14.90 | 2021 | |
| Vivus LLC | $14.52 | 2022 | |
| Phathom Pharmaceuticals, INC. | $8.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cesario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.